Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most AMLs with CEBPA mutations simultaneously carry 2 mutations (CEBPA(double-mut)), usually biallelic, whereas single heterozygous...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Wouters, Bas J., Löwenberg, Bob, Erpelinck-Verschueren, Claudia A. J., van Putten, Wim L. J., Valk, Peter J. M., Delwel, Ruud
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2009
נושאים:
Myeloid Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2662648/
https://ncbi.nlm.nih.gov/pubmed/19171880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-09-179895
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים